Benzimidazolone compounds having 5-HT4 receptor agonistic activity

Details for Australian Patent Application No. 2004268840 (hide)

Owner Pfizer Inc.

Inventors Iguchi, Satoru; Uchida, Chikara; Kojima, Takashi; Sone, Hiroki; Katsu, Yasuhiro

Agent Spruson & Ferguson

Pub. Number AU-B-2004268840

PCT Pub. Number WO2005/021539

Priority 60/500,144 03.09.03 US

Filing date 20 August 2004

Wipo publication date 10 March 2005

Acceptance publication date 23 September 2010

International Classifications

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

C07D 405/06 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

16 March 2006 PCT application entered the National Phase

  PCT publication WO2005/021539 Priority application(s): WO2005/021539

23 September 2010 Application Accepted

  Published as AU-B-2004268840

20 January 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004268847-Inhibitors of phosphodiesterase type-IV

2004268839-Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists